Cencora's 0.28% Drop Amid $490M Volume Lands It 360th in U.S. Equity Trading

On September 19, 2025, , , . equity trading activity. The pharmaceutical services provider saw limited directional movement amid mixed sector sentiment.

A key development highlighted was a strategic partnership with a mid-cap drug manufacturer to expand its specialty pharmacy services. The collaboration, announced earlier in the week, aims to streamline supply chain logistics for oncology treatments but lacks immediate revenue-sharing details. Analysts noted the agreement could strengthen Cencora’s market position in niche therapeutic areas without providing near-term earnings catalysts.

Short-term technical indicators showed muted momentum, with the stock failing to break above its 50-day moving average. , though this does not directly correlate to the partnership announcement. Market participants remain focused on the company’s third-quarter earnings release scheduled for late October.

I understand the idea: each trading day, , buy them, , . To implement this rigorously, . Universe • “All U.S. listed common stocks” is technically possible, but pulling daily volume for thousands of tickers will be slow. • A common compromise is to work within a defined index (e.g., . 2. , . . 3. , or do we simply use the current constituent list? Once these points are fixed, . • Rank each day, . . , volatility, , , etc., . Please let me know your preference on the three items above so I can proceed with the data-pull and backtest.